Fasting during immunotherapy: a new way to boost treatment?
NCT ID NCT07645742
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether intermittent fasting is safe and doable for people with advanced solid tumors who are starting immunotherapy. About 90 participants will be split into three groups: no fasting, eating only during an 8-hour window each day, or fasting every other day. Researchers will track how well people stick to the diet, side effects, fatigue, sleep, and quality of life over about 20-24 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill outperform chemo for a Hard-to-Treat lung cancer mutation?
- Can a Triple-Drug combo outsmart Immunotherapy-Resistant lung cancer?
- Which palliative care approach boosts quality of life in advanced lung cancer?
- Can a new biologic drug shrink advanced melanoma tumors?
- Can a smart drug deliver a toxic payload directly to cancer cells?
- Experimental drug combo targets Hard-to-Treat lung cancer